Document is current
Any future updates will be listed below
-
Authors
Saidkasimova, Shohista https://orcid.org/0000-0001-8872-6313
Lee, Chan Ning
Murphy, George S. P.
Jackson, Timothy L. https://orcid.org/0000-0001-7618-1555
,
Chandra, Aman
Cornish, Kurt Spiteri
Desai, Riti
Houghton, Kirsteen
Laidlaw, David A
Steel, David
Timson, Noimot
-
Funding
Funding for this research was provided by:
Norfolk and Norwich University Hospitals NHS Foundation Trust (365)
BEAVRS (2019)
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 11 February 2026
First Online: 17 March 2026
Declarations
:
: The VIKING study has been approved by the East Midlands Leicester Central Research Committee, number 21/EM/0088, on the 7th June 2021.
: Not applicable.
: TLJ is a consultant/advisor to 2CTech; Alcon; Dutch Ophthalmic Research Centre (DORC); iLumen; Opthea; Outlook Therapeutics; Oxurion; Pfizer; Regeneron. He received conference support from Roche. TLJ, CNL, and GM NHS employer receives site fees for patients enrolled on commercial retinal trials and free use of equipment or drugs for investigator-initiated trials from LKC, Zeiss, and Bayer. SS is an advisor for Alcon, DORC, Roche.
